The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Intravesical disitamab vedotin (RC48) for patients with HER2-expressing high-risk non-muscle-invasive bladder cancer: A dose-escalation phase I trial.
 
Xu Chen
No Relationships to Disclose
 
Ming Huang
No Relationships to Disclose
 
Jianmin Fang
Employment - RemeGen
Leadership - RemeGen
Stock and Other Ownership Interests - RemeGen
 
Jian Huang
No Relationships to Disclose
 
Tianxin Lin
No Relationships to Disclose